This initial assessment is crucial for accurate risk assessment, initiation of induction therapy based on the presence of somatic mutations, e.g., FLT3-ITD, IDH mutations or KMT2A rearranged AML or CBF AML, and in making decisions regarding post-induction consolidation strategies. Here, FLT3 is linked to acute myeloid leukemia.